预约演示

Gilead puts 3 programs on chopping block, including 2 of 3 indications for IRAK4 inhibitor IRAK4 inhibitor

2023-02-03

临床1期细胞疗法

The pipeline changes leave the IRAK4 inhibitor GS-5718 only continuing on in lupus.

With so many Big Pharmas reportIRAK4 inhibitor IRAK4heir full-yGS-5718nings yesterday, it waslupusurprise that drugmakers used the occasion as an excuse to slip out some pipeline changes. Gilead was no exception, removing a solid tumor candidate from its early-stage lineup along with two of the three indications for its IRAK4 inhibitor.

One asset on the chopping block is a Fms-like tyrosine kinase 3 agonist dubbed GS-3583 that was being assessed in a phase 1b trial for patients with advanced solid tumors. Gilead terminated the 13-patient trisolid tumorrly following an internal safety assessment of the molecule, according to ClinicalTrialIRAK4 inhibitor IRAK4.

The other two programs being cut are Fms-like tyrosine kinase 3 agonist Fms-like tyrosine kinase 3inflammatory disGS-3583ndidate: an interleukin-1 receptor-associated kinase 4, or IRAKadvanced solid tumorsS-GileadGilead is ending early-stage work evaluating the therapy in both inflammatory bowel disease and rheumatoid arthritis. It leaves GS-5718 only continuing on in lupus, according to Gilead’s earnings presentation.

The IRAK-4 field received some positive coverage in December whinflammatory diseasecs linked its ointerleukin-1 receptor-associated kinase 4f hidIRAK4itis suppurativa anGS-5718c Gileaditis, encouraging its partner Sanofi to take the program foinflammatory bowel disease5718,rheumatoid arthritisgrades, rathGS-5718 inhibits, IRAK-4.lupus Gilead

GileIRAK-4n’t alone in disclosing pipeline changes yesterday. The Kymera Therapeuticsed its earnings call after market close, joined four othehidradenitis suppurativa Lillatopic dermatitisd Bristol Myers Squibb—thaSanofi shared program cuts earlier in the dGileadparGS-5718eiKymeraearnings announcements.IRAK-4

Gilead the California-based pharma touts 59 clinical programs and has more than doubled its pipeline programs over the last four years, CEO Daniel O’Day andRochef Eli LillyffMerck & Co. ParsBristol Myers Squibb on a post-market call with investors.

The company—which anticipates an FDA decision for an expanded indication of its potential breast cancer blockbuster Trodelvy later this month—saw an increase in quarterly R&D spend driven by clinical studies in oncology and virology. The pharma has also buckled down on investing in its cell therapy pipeline, as highlighted in a recent $225 million deal with Arcellx.

“We're going into 2023 in a very FDAong position with our current medicines performing welbreast cancerous growth potential in our newer therapies, as well as those in development,” O’Day concluded. “What you can expect to see next is quarter-on-quarter execution, and even faster progress and greater impact in the future.”Arcellx

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构